CHAPEL HILL, NC--(Marketwired - Mar 26, 2014) - Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a corporate overview at the MaidStone Life Sciences LLC 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference on March 27, 2014 at 10:30 a.m. Eastern Time at the New York Academy of Medicine in New York City.
Heat's Vice President of Research and Development, Taylor H. Schreiber, M.D., Ph.D. will also participate as a panelist for the Emerging Role of Combination Therapy discussion scheduled on March 27 at 9:30 a.m. Eastern Time.
A live audio webcast of Mr. Wolf's presentation will be available in the Investors section of the Heat Biologics' website at www.heatbio.com. The webcast will be archived on the Company's website for 30 days following the event.
About MaidStone Life Sciences Cancer Immunotherapy Conference
On Thursday, March 27, 2014 from 8:00 a.m. to 6:30 p.m. Eastern Time, MaidStone Life Sciences LLC will host the Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City. This unique, single-day conference event unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.
About Heat Biologics, Inc.
Heat Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat will be entering Phase 2 trials with its HS-110 against non-small cell lung cancer and is conducting Phase 1/2 clinical trials with its HS-410 against bladder cancer. For more information, please visit www.heatbio.com.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat's ImPACT Therapy and the expected trial results. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.